

1 **Characterising COVID-19 empirical research production in Latin America and the** 2 **Caribbean: a scoping review**

3 Cristián Mansilla^{1¶}, Cristian A. Herrera^{2,3¶}, Laura Boeira⁴, Andrea Yearwood⁵, Analia S. Lopez⁶, Luis E.
4 Colunga-Lozano⁷, Eva Brocard⁸, Tatiana Villacres⁹, Marcela Vélez¹⁰, Gabriel Di Paolantonio¹¹, Ludovic
5 Reveiz¹².

6 ¹ McMaster Health Forum and Health Policy PhD Program, McMaster University, Hamilton, Canada

7 ² Department of Public Health, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile

8 ³ The World Bank Group, Washington, DC, USA

9 ⁴ Instituto Veredas, Porto Alegre, Brazil

10 ⁵ Independent researcher, Port of Spain, Trinidad and Tobago

11 ⁶ Instituto Universitario CEMIC (IUC), Buenos Aires, Argentina

12 ⁷ Department of clinical medicine, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico

13 ⁸ Independent researcher, Paris, France

14 ⁹ Quantics, Quito, Ecuador

15 ¹⁰ Faculty of Medicine, Universidad de Antioquia, Medellin, Colombia

16 ¹¹ PhD in Economics Program, University of Paris 1, Paris, France

17 ¹² Pan American Health Organization, Incident Management Systems for COVID-19 and Evidence and
18 Intelligence for Action in Health Department, Washington, DC, USA

19

20 *Corresponding authors:

21 E-mails: camansil@gmail.com (CM), crherrer@uc.cl (CAH).

22

23 ¶ These authors contributed equally to this work.

24 **ABSTRACT**

25 **Introduction**

26 The Coronavirus Disease 2019 (COVID19) pandemic has struck Latin America and the Caribbean (LAC)
27 particularly hard. One of the crucial areas in the international community's response relates to accelerating
28 research and knowledge sharing. The aim of this article is to map and characterise the existing empirical research
29 related to COVID-19 in LAC countries and contribute to identify opportunities for strengthening future research.

30 **Methods**

31 In this scoping review, articles published between December 2019 and 11 November 2020 were selected if they
32 included an empirical component (explicit scientific methods to collect and analyse primary data), LAC
33 population was researched, and the research was about the COVID-19 pandemic, regardless of publication status
34 or language. MEDLINE, EMBASE, LILACS, Scielo, CENTRAL and Epistemonikos were searched. All titles
35 and abstracts, and full texts were screened by two independent reviewers. Data from included studies was
36 extracted by one reviewer and checked by a second independent reviewer.

37 **Results**

38 14,406 records were found. After removing duplicates, 5,458 titles and abstracts were screened, of which 2,323
39 full texts were revised to finally include 1,626 empirical studies. The largest portion of research came from
40 people/population of Brazil (54.6%), Mexico (19.1%), Colombia (11.2%), Argentina (10.4%), Peru (10.3%) and
41 Chile (10%), while Caribbean countries concentrated 15.3%. The methodologies most used were cross-sectional
42 studies (34.7%), simulation models (17.5%) and randomized controlled trials (RCTs) (13.6%). Using a modified
43 version of WHO's COVID-19 Coordinated Global Research Roadmap classification, 54.2% were
44 epidemiological studies, followed by clinical management (22.3%) and candidate therapeutics (12.2%).
45 Government and public funds support were reported in 19.2% of studies, followed by universities or research
46 centres (9%), but 47.5% did not include any funding statement.

47 **Conclusion**

48 During the first part of the COVID-19 pandemic, LAC countries have contributed to the global research effort
49 primarily with epidemiological studies, with little participation on vaccines research, meaning that this type of

50 knowledge would be imported from elsewhere. Research agendas could be further coordinated aiming to
51 enhance shared self-sufficiency regarding knowledge needs in the region.

52

53 **INTRODUCTION**

54 The Coronavirus Disease 2019 (COVID-19) pandemic has struck Latin America and the Caribbean (LAC)
55 particularly hard, having substantial health, social and economic consequences for the population living in this
56 Region. By mid-July 2021, over 1,300,000 COVID-19 deaths have been reported in the region(1), along with an
57 estimated reduction of 7.4% in gross domestic product (GDP), only in 2020(2). The pandemic seems more
58 difficult to bring under control comparing with other parts of the world, considering that the LAC region has
59 particularly high levels of inequality and labour informality, with comparatively weaker social protection
60 schemes, along with health systems feebly prepared to boost test, track and trace programmes and to face high
61 demand surges for specialised intensive care(3).

62 At the global level, one of the crucial areas in the international community's response to COVID-19 relates to
63 accelerating research, innovation and knowledge translation and sharing(4). On 11 and 12 February 2020, the
64 Global Research Forum, hosted by WHO, developed an initial COVID-19 Global Research Roadmap with two
65 main aims: "1. to facilitate that those affected are promptly diagnosed and receive optimal care; while integrating
66 innovation fully within each research area; and 2. to support research priorities that will lead to the development
67 of sustainable global research platforms that are prepared for the next disease X epidemic"(5). Back then, this
68 Forum identified groups actively researching on COVID19 in Africa, Australia, Europe and North America, but
69 no mention was made of LAC.

70 Despite these global efforts to encourage research collaboration across countries and regions, it is not known if
71 the research that has been conducted in LAC in response to the COVID-19 crisis accounts for the impact that the
72 pandemic is having in the region. A literature review conducted in April 2020 found that only 2.7% of the total
73 publications related to COVID-19 had at least one author with a Latin American-based affiliation(6), showing
74 some insights of the relatively low development of research in LAC at that time. This was corroborated with

75 subsequent bibliometric studies showing the same low participation of LAC(7) (8). A more recent report of the
76 Organisation for Economic Cooperation and Development(9) analysed 74 115 COVID-19 documents in PubMed
77 during the period 1 January to 30 November 2020, finding that in terms of author’s affiliation the United States
78 represented 23% and the European Union 22% of all documents, followed by China, the United Kingdom and
79 India. The top collaboration partnerships also occurred between these countries, signaling that the LAC region
80 has not significantly participated in COVID-19 research production.

81 Additionally, understanding the development of research during the COVID-19 pandemic becomes especially
82 relevant and necessary as we have seen a “coviditisation” of research(10). This has brought challenges related to
83 redundancy and research waste, leaving other relevant fields unattended, or with a diminished research quality.
84 For instance, a paper evaluating the characteristics and expected strength of evidence of COVID-19 studies
85 registered on ClinicalTrials.gov found that only 29.1% have the potential to result in OCEBM level 2 evidence
86 (good-quality evidence) and that of the randomised clinical trials protocols, only 29.3% are placebo-controlled,
87 blinded studies(11). More recently, we learned that researchers registered more than 2,900 clinical trials related
88 to COVID-19, but the majority were too small or poorly designed, and in some cases there have been an excess
89 of trials for molecules of questionable therapeutic benefit (e.g. hydroxychloroquine)(12). In addition, research
90 funding has also been questioned in terms of the distribution and sources for achieving a fair and sustainable
91 research and development environment(13). In LAC, a study searching for COVID-19 trials on treatment and
92 prevention in the region identified “a trend towards small repetitive non-rigorous studies that duplicate efforts
93 and drain limited resources without producing meaningful conclusions on the safety and efficacy of the
94 interventions being tested”(14). However, apart from this study it is unknown what are the trends of empirical
95 research in LAC during the COVID-19 pandemic, in a context where institutional development for health
96 research has progressed in the region but has been reported as generally uncoordinated and disaggregated, and
97 uneven between countries(15).

98 Considering the large impact that COVID-19 has had in LAC and the relevance of research for the COVID-19
99 response, there is a need to better understand how research production has unfolded in the region to inform
100 contextually relevant decision making. The aim of this article is to map and characterise the existing empirical

101 research related to COVID-19 in LAC countries during the pandemic and contribute to identify opportunities for
102 strengthening research for the future.

103 **METHODS**

104 This is a scoping review of the existing empirical research produced in LAC countries related to COVID-19
105 pandemic.

106 Eligibility criteria

107 Articles in any language were eligible. To be included:

- 108 ● articles needed to be empirical research demonstrated by the report of the scientific methods used to
109 collect and analyze the primary data;
- 110 ● the population being researched must include people from at least one LAC country or their explicit
111 focus is on one or more LAC countries. LAC countries considered are Antigua and Barbuda, Argentina,
112 Bahamas, Barbados, Belize, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Dominica, Dominican
113 Republic, Ecuador, El Salvador, Grenada, Guatemala, Guyana, Haiti, Honduras, Jamaica, Mexico,
114 Nicaragua, Panama, Peru, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines,
115 Suriname, Trinidad and Tobago, Uruguay, and Venezuela;
- 116 ● the research must be directly or explicitly connected to the current COVID-19 pandemic.

117 Articles were excluded if they:

- 118 ● were any type of evidence synthesis of the literature, or documents building on evidence syntheses (e.g.,
119 guidelines, recommendations, consensus, systematic reviews, etc.);
- 120 ● used large international databases and their explicit focus was not in one or more LAC countries;
- 121 ● were not using empirical data to build their findings (including clinical case report).

122 Articles were included regardless of their study design, topic and publication date. Simulation studies were also
123 included if they considered empirical data to build on a specific model (e.g., case counts, tests, etc.).

124 Search methods

125 To identify potentially relevant documents, the following bibliographic databases were searched:

- 126 ● MEDLINE and EMBASE using Ovid (December 2019 to 11 November 2020)
- 127 ● LILACS (using VHL) (inception to 11 November 2020)
- 128 ● Scielo (2019 to 11 November 2020)
- 129 ● CENTRAL (2019 to 11 November 2020)
- 130 ● Epistemonikos (2019 to 11 November 2020).

131 To identify grey literature, registry of trials, and pre-print articles, the electronic database search was also
132 supplemented by searching the Living Overview of the Evidence (L-OVE) COVID-19 Repository by the
133 Epistemonikos Foundation, and searching the references of evidence syntheses that were found when assessing
134 the eligibility of the articles. Additionally, registries for studies that are planned to be conducted were
135 complemented with the clinical trials found by Carracedo S et al. 2021(14). The search strategies that were used
136 in each database are described in the S1 Supporting information 1.

137 Study selection

138 Duplicates were removed using EndNote® and Covidence®. All title and abstracts, and full texts were screened
139 by two independent reviewers, resolving disagreements by a third reviewer, or a formal discussion between the
140 two involved reviewers. Covidence® was used to conduct this process.

141 Data extraction and charting

142 From the included articles, data was extracted by one reviewer, and was checked by a second independent
143 reviewer, agreeing on what data to extract from each study. The following characteristics of the included studies
144 were extracted (see S1 Supporting information 2 for a complete description of each item extracted):

- 145 ● Lead author, month, year, and citation
- 146 ● Data sources, classified as inert sources, animals, directly humans, databases or documents.
- 147 ● Main objective of the article and research question classified as exposure, prevalence or incidence,
148 benefits and harms of an intervention, prognosis, views and preferences, diagnostic accuracy, or other.

- 149 ● Methods and study design of each study, identifying basic sciences, quantitative, qualitative or mixed-
150 methods studies.
- 151 ● Type of intervention, exposure, or phenomenon of interest being addressed, using the 9 main research
152 areas outlined by the World Health Organization in their Global Research Roadmap(5), and adding
153 health systems arrangements as one key area. In addition, a “Other” category was added to include
154 topics like the impact of the pandemic in mental health.
- 155 ● Countries of the LAC region where the research is being targeted.
- 156 ● Funding of the study, classified as government and public funds, international organizations, universities
157 or research centres, NGOs, private companies, public private entities, or others.
- 158 ● Journal or website where the study was published.
- 159 ● Status of publication.

160 The data extraction template was piloted with 10 studies by two authors, and the full data extraction process was
161 conducted in Microsoft Excel ®.

162 Data synthesis

163 With the information collected from each study, descriptive information is presented to characterize the research
164 that was being conducted on LAC countries.

165 The total volume of research that was produced by month is presented, and the number of publications per
166 country is analyzed, showing absolute numbers and a rate of publications per population for the countries with
167 more than 1,000,000 inhabitants. Rate per the number of researchers in each country is also calculated, based on
168 the information published by UNESCO(16). The geographical information is presented in interactive maps using
169 Tableau® software.

170 Summaries of the main data sources used, methodologies and study designs, type of research questions and
171 sources of funding are also calculated.


172 Finally, descriptive summaries of the number of publications addressing each one of the modified WHO Global
173 Research Roadmap categories are also presented.

174 **RESULTS**

175 **Search results**

176 14,406 records were found. After removing duplicates, 5,458 titles and abstracts were screened, of which 2,323
177 full texts were revised to finally include 1,626 empirical studies. See Figure 1 for the flow diagram of the review.
178 A full list of included and excluded studies, along with the reasons for exclusion, is provided in the S1
179 Supporting information 3.


180 **Figure 1. Flow diagram for the scoping review of empirical research related to COVID-19 in LAC**
181 **countries**



183 **Timing and status of the publication**

184 Among the 1,626 publications included in this analysis, the month on which it was available to the public is
185 shown in Figure 2. The number of publications had a sharp increase from the start of the pandemic, starting
186 mainly in March and reaching the peak in July. The level kept relatively constant over 200 publications per
187 month between May and September. 5 of the articles did not report the month in which it was available, while 1
188 of them was retracted from the journal. Most articles were published in scientific journals (886; 55%), followed
189 by pre-print versions (444; 27%) and registries (287; 18%).

190 **Figure 2. Number of empirical studies published per month from February to 11 November 2020.**



191

192 **Geographical distribution**

193 In terms of the geographical distribution of the COVID-19 empirical research, all 33 countries in the region had
194 at least one publication conducted in their population. There were 5 articles for which the country was not
195 mentioned, but the authors did mention that they include at least one country from the LAC region.


196 Brazil concentrated most of inclusions in publications with 54.6% of the total, followed by Mexico (19.1%),
197 Colombia (11.2%), Argentina (10.4%), Peru (10.3%), and Chile (10%), while Caribbean countries concentrated
198 15.3% of studies. Uruguay, Panama, Trinidad and Tobago, Chile and Costa Rica had the highest rate of

199 empirical studies published per population with 14.9, 9.7, 9.3, 8.5 and 8 studies per 1 million population
200 (excluding countries with less than 1 million population). Haiti and Venezuela were the only two countries with
201 less than 2 publications per 1 million population.

202 179 studies (11%) were conducted in several countries including countries outside of the Region, whereas 151
203 were conducted in more than one country, but only in the Region.

204 **Figure 3. Empirical studies related to COVID-19 in each LAC country.**

205 **3a. Total number of publications per country / 3b. Rate of number of publications per 1,000,000**
206 **population, excluding countries with less than 1,000,000 population**



207

208 Note: Figures underlying data can be found in [https://public.tableau.com/views/LACCOVIDresearch-](https://public.tableau.com/views/LACCOVIDresearch-scopingreview/publicationspercountry?:language=en-US&publish=yes&:display_count=n&:origin=viz_share_link)
209 [scopingreview/publicationspercountry?:language=en-US&publish=yes&:display_count=n&:origin=viz_share_link](https://public.tableau.com/views/LACCOVIDresearch-scopingreview/publicationspercountry?:language=en-US&publish=yes&:display_count=n&:origin=viz_share_link)

210 **Data sources, methods and research questions**

211 Most studies obtained its information directly from humans (54.7%), followed by databases (41.9%). Only 4.2%
212 of studies used documents as data sources and 1.2% used inert sources (e.g. basic science studies). Qualitative
213 methods were used by 4.9% of studies and 3.1% were basic sciences studies. Almost 92% of studies applied

214 quantitative methods, with the majority of them using cross-sectional (34.7%), modelling methods (17.5%) and
 215 RCTs (13.6%). 221 studies were identified as RCTs of which 207 were ongoing studies at the time of the search.
 216 Most research questions were related to exposure, prevalence or incidence (66.4%), followed by benefits and
 217 harms of an intervention (21.5%) and prognosis (6.7%). See Table 1 for details.

218 **Table 1. Data sources, methods and research questions of empirical research related to COVID-19 in LAC**
 219 **countries**

	Number	Percentage of the total number of publications *
Data sources		
Inert sources	19	1.2%
Animals	3	0.2%
Directly humans	889	54.7%
Databases	682	41.9%
Documents	69	4.2%
Not described	8	0.5%
Other	27	1.7%
Methodology		
Basic sciences	50	3.1%

Quantitative		
Randomized controlled trial	221	13.6%
Cohort study	143	8.8%
Cross-sectional study	564	34.7%
Ecological study	103	6.3%
Modelling study	285	17.5%
Other**	184	11.3%
Qualitative	79	4.9%
Mixed-methods	8	0.5%
Type of research questions		
Exposure, prevalence or incidence	1079	66.4%
Benefits and harms of an intervention	350	21.5%
Prognosis	109	6.7%
Views and preferences	63	3.9%
Diagnostic accuracy	39	2.4%
Other	210	12.9%

220 *% sum more than 100% because one article could have more than one category.

221 ** Other include several types of study design such as time series, before-and-after, case-control, and economic


222 evaluations.

223

224 WHO Coordinated Global Research Roadmap classification of COVID-19 research

225 According to the modified version of the WHO Coordinated Global Research Roadmap classification of
226 COVID19 research, 54.2% were epidemiological studies, followed by clinical management (22.3%), candidate
227 therapeutics (12.2%), health systems arrangements (10.1%), and infection prevention and control (8.8%). Only
228 eleven studies were identified regarding vaccines for COVID19 and 198 studies for candidate therapeutics.

229 **Figure 4. Number of publications per thematic areas of empirical research related to COVID-19 in LAC**
230 **countries, using the WHO COVID-19 research roadmap.**



231

232 Funding sources

233 The majority of papers that were included in these analyses did not report their funding source (47.5%) or did
234 not have a specific source of funding (21.8%). Governments and the public sector contributed funding to 19.2%
235 of papers, followed by universities and research centres with 9%. NGOs contributed to 2.4% of studies and the
236 private sector to 4.9% (Table 2).

237 **Table 2. Funding sources of empirical research related to COVID-19 in LAC countries**

Funding source	Number	% of the number or publications
Government and public funds	312	19.2%
International organizations	32	2.0%
Universities or research centres	147	9.0%
NGOs	39	2.4%
Private companies	79	4.9%
Public private entity	3	0.2%
Other	10	0.6%
Not reported	772	47.5%
None	355	21.8%

238 *% sum more than 100% because one article could have more than one category.

239

240 **DISCUSSION**

241 Research production in LAC during the first part of the COVID-19 pandemic surpassed 1600 empirical studies.

242 This number is difficult to compare with other regions as there are not many studies exploring this issue. To our

243 knowledge, only the bibliometric analysis for Africa conducted by Guleid et al. 2021(17) included "research

244 involving the collection and analysis of primary data" that would be similar to our definition of "empirical

245 research". In this case, they found 606 studies between December 2019 and December 2020, which would be

246 close to a third of what the present review found for LAC.

247 Empirical COVID-19 studies were found in all LAC countries, but were mainly concentrated in six countries
248 that accounted for almost three quarters of all the included papers (Brazil, Mexico, Colombia, Peru, Chile and
249 Argentina), while Uruguay, Panama, Trinidad and Tobago, Chile and Costa Rica had the highest rate of
250 publications per population, with Haiti and Venezuela having the lowest. This coincides with other studies
251 finding a similar list of countries at the top and bottom of research production among LAC countries, for
252 instance during the COVID-19 pandemic with oncology clinical trials (18) and before the pandemic with
253 pharmacological RCTs (19) and clinical trials (20). The latter also found that over 80% of trials were
254 concentrated in three countries (Brazil, Mexico and Argentina), while the present review found a larger
255 participation of other LAC countries as well, showing that the pandemic probably has pushed for a more country
256 widespread research generation.

257 Much of the research production was conducted using observational and simulation methods, with more than
258 half of the publications classified as epidemiological studies, which correlates with the fact that two thirds of
259 papers studied issues related to exposure, prevalence or incidence of COVID-19. Remarkably, 198 studies for
260 candidate therapeutics and only 11 studies exploring candidate vaccines were found, signaling a relatively low
261 participation of LAC population in this type of research. This is more worrying due to the fact that RCTs
262 protocols for such studies have also been found to be of low quality and potential waste of research resources
263 (14). This finding might have implications for understanding the actual effects of different health technologies
264 on the region's population, as most of the COVID-19 scientific knowledge would need to be imported from
265 elsewhere. A similar situation was described in Africa, where a bibliometric analysis found that only 13 studies
266 (1% of the total studies found) were about therapeutics and vaccines for COVID-19(17).

267 Health systems research and social sciences in response to the COVID-19 pandemic had a relatively low
268 presence, which limits the understanding of national and local realities in LAC health systems and societies,
269 hindering decision making. On a related note, the WHO Coordinated Global Research Roadmap classification of
270 COVID-19 research did not include an explicit category for health systems research and did not explicitly
271 include other important issues such as mental health, which was included separately in our classification.

272 Regarding funding sources, close to half of studies (47.5%) did not report their funding provenance. This is
273 higher than what has been reported in previous research, for instance related to health policy and systems
274 research(21) and clinical trials(22) where 31% and 11% of studies, respectively, did not include funding
275 statements. Among the studies that reported funding source, government and public sector sources were the most
276 prevalent, while private sector sources were the least reported. This is also different from the Africa region
277 where most of funding for COVID-19 research comes from international and foreign entities(17). In LAC, these
278 findings could highlight opportunities to collaborate and create synergies between public and academic funding
279 sources, where national health research agendas could help to align priorities and efforts(23). During the
280 COVID-19 pandemic, some LAC countries developed programmes aiming to adapt their research production in
281 the short term. Some examples can be found in Chile with the National Agency of Research and Development
282 that created a special fund of USD 300,000 where researchers applied to receive grants for relevant COVID-19
283 research(24); the Brazilian Ministries of Science and Technology and Health also launched public calls for
284 COVID-19 research in 2020, totaling USD 42 million(25); and in Argentina the National Agency for Research,
285 Development and Innovation financed COVID-19 research projects for a total of USD 2,5 million(26). Despite
286 COVID-19 being a global and regional challenge, these government initiatives could have an explicit
287 international coordination focus, which could boost synergies and expand the impact of future research in LAC.
288 LAC countries can use the findings of this review to understand their research production in times of a global
289 public health emergency, which can help to identify areas of relative high research volume (e.g. epidemiologic
290 and simulation studies) and potentially research gaps (e.g. vaccines and therapeutics) to improve collaboration
291 between countries in the region and externally; for instance, to expand networks, to look for and pool funds, to
292 improve surveillance systems, and to boost the production and quality of data and studies(27). There is also a
293 need to build capacity to have more flexible research production in order to act fast in responding to public
294 health emergencies such as pandemics, which can be readily translated to decision making at different levels of
295 health and social systems(28). This seems especially relevant to research linked to existing or developing data
296 systems. Strengthening the data infrastructure has been identified by international organizations such as OECD
297 and WHO/PAHO as essential for managing health systems affected by a pandemic. Having a strong R&D

298 infrastructure analysing these data may help to improve the overall quality of data and hence health system
299 performance management. The need for LAC to become more self-sufficient in the production of vaccines, tests,
300 personal protective equipment, and genome sequencing has been recognised(29), and this can be broadened to
301 health system performance management and research capacities, which will be key to make this happen(30).

302 **Strengths and limitations of the review**

303 This review has several strengths. Firstly, to our knowledge, this is the first study systematically mapping and
304 characterising all empirical research produced in response to COVID-19 in LAC. Secondly, while most of the
305 studies exploring COVID-19 research production have had a broad bibliometric focus (e.g. counting the total
306 number of publications, not differentiating by their empirical nature), this review only includes empirical studies
307 using at least some basic scientific method that have a higher likelihood of contributing with novel information
308 to literature and decision making. Thirdly, most of the studies exploring countries' involvement in COVID-19
309 research have looked for author's affiliation, as opposed to the actual participation of country's people or
310 population, which is the main focus of this review. Finally, while evidence syntheses often consider certain type
311 of study designs in their inclusion criteria, this review gathers all relevant empirical research, including all type
312 of study designs and methods (e.g., modelling studies, basic science, etc.).

313 Among the limitations of this review, we could only report the month of the studies at the time the searches were
314 conducted, which might have missed some studies that became publicly available later but with earlier dates of
315 publication. Another limitation relates to the possibility that some studies might have not explicitly described the
316 scientific methods used to collect and analyze the primary data, so even if they were empirical, we might have
317 excluded them because of the review criteria. In addition, the UNESCO researcher rate was not available for all
318 the countries, which limited the possibility of including the whole region in the publication rate per researchers
319 (Figure 3). Also, although the review did not search directly in trials registries, the databases that were searched
320 actively search all trial registries, such as the LOVE platform and CENTRAL. To make the search even broader,
321 the included studies of Carracedo et al. 2021(14), which searched thoroughly in such registries, were reviewed
322 and included when relevant. Finally, included studies were not critically appraised in this review, and therefore
323 the quality of research cannot be assessed.

324 **CONCLUSION**

325 During the first part of the COVID-19 pandemic, LAC countries have contributed to the global research effort
326 primarily with epidemiological studies, with little participation on vaccines, meaning that this type of knowledge
327 would be imported from elsewhere. All LAC countries produced COVID-19 empirical research. Research
328 agendas could be further coordinated between different actors within and among LAC countries aiming to
329 enhance shared self-sufficiency to respond to the knowledge needs in the region, especially considering that
330 most of the declared research funding came from public and academic sources.

331

332 **AUTHORS CONTRIBUTIONS**

333 CM and CAH contributed equally to this paper. CAH and CM conceived the idea and the protocol. CM, CAH,
334 LB, AY, ASL, LECL, EB, TV, MV and GDP participated in the screening and extraction. CM performed data
335 analysis with inputs from CAH. CAH led the article writing, with inputs from CM and LR. All authors read and
336 approved the final version.

337

338 **ACKNOWLEDGEMENTS**

339 We acknowledge and thank Gloria Carmona for her contributions in the abstract screening process and Dr Niek
340 Klazinga from the Amsterdam University Medical Centre (AMC/UvA) for providing feedback on the initial
341 findings.

342

343 **COMPETING INTERESTS**

344 The authors have declared that no competing interests exist. Authors hold sole responsibility for the views
345 expressed in the manuscript, which may not necessarily reflect the opinion or policy of the Pan American Health
346 Organization nor the World Bank Group.

347

348 **FUNDING INFORMATION**

349 The author(s) received no specific funding for this work.

350

351 **REFERENCES**

- 352 1. PAHO/WHO. PAHO Daily COVID-19 Update: 14 July, 2021 [Internet]. 2021 [cited 2021 Jul 15].
353 Available from: <https://www.paho.org/en/documents/paho-daily-covid-19-update-14-july-2021>
- 354 2. IMFBlog. Latin America and Caribbean’s Winding Road to Recovery [Internet]. IMF Blog. [cited 2021 Jul
355 15]. Available from: <https://blogs.imf.org/2021/02/08/latin-america-and-caribbeans-winding-road-to-recovery/>
356
- 357 3. OECD/The World Bank. Health at a Glance: Latin America and the Caribbean 2020 [Internet]. Paris:
358 OECD Publishing; 2020 [cited 2021 Jul 15]. Available from: <https://doi.org/10.1787/6089164f-en>
- 359 4. WHO. COVID-19 strategy update (as of 14 April 2020). *Weekly Epidemiological Record*. 95(19):185–
360 208.
- 361 5. WHO. A Coordinated Global Research Roadmap [Internet]. 2020 [cited 2021 Jul 15]. Available from:
362 <https://www.who.int/publications/m/item/a-coordinated-global-research-roadmap>
- 363 6. Fiesco-Sepulveda KY, Serrano-Bermudez LM. Contributions of Latin American researchers in the
364 understanding the novel coronavirus outbreak: A literature review. 2020 May 22 [cited 2021 Jul 15];
365 Available from: <https://covid19-evidence.paho.org/handle/20.500.12663/1794>
- 366 7. Zyoud SH, Al-Jabi SW. Mapping the situation of research on coronavirus disease-19 (COVID-19): a
367 preliminary bibliometric analysis during the early stage of the outbreak. *BMC Infect Dis*. 2020
368 Dec;20(1):561.
- 369 8. Dehghanbanadaki H, Seif F, Vahidi Y, Razi F, Hashemi E, Khoshmirisafa M, et al. Bibliometric analysis of
370 global scientific research on Coronavirus (COVID-19). *Med J Islam Repub Iran*. 2020 May 23;34:51.
- 371 9. OECD. OECD Science, Technology and Innovation Outlook 2020: Science and Innovation in Times of
372 Crisis [Internet]. OECD; 2021 [cited 2021 Jul 15]. (OECD Science, Technology and Innovation Outlook).
373 Available from: https://www.oecd-ilibrary.org/science-and-technology/oecd-science-technology-and-innovation-outlook-2021_75f79015-en
374
- 375 10. Pai M. Covidization of research: what are the risks? *Nat Med*. 2020 Aug;26(8):1159–1159.
- 376 11. Pundi K, Perino AC, Harrington RA, Krumholz HM, Turakhia MP. Characteristics and Strength of
377 Evidence of COVID-19 Studies Registered on ClinicalTrials.gov. *JAMA Intern Med*. 2020 Oct
378 1;180(10):1398.
- 379 12. Pearson H. How COVID broke the evidence pipeline. *Nature*. 2021 May 13;593(7858):182–5.
- 380 13. Prudêncio M, Costa JC. Research funding after COVID-19. *Nat Microbiol*. 2020 Aug;5(8):986–986.

- 381 14. Carracedo S, Palmero A, Neil M, Hasan-Granier A, Saenz C, Reveiz L. El panorama de los ensayos
382 clínicos sobre COVID-19 en América Latina y el Caribe: evaluación y desafíos. *Revista Panamericana de*
383 *Salud Pública*. 2021 Mar 8;45:1.
- 384 15. Becerra-Posada F, Minayo M, Quental C, de Haan S. National research for health systems in Latin
385 America and the Caribbean: moving towards the right direction? *Health Res Policy Sys*. 2014 Mar
386 6;12(1):13.
- 387 16. UNESCO. UNESCO science report: towards 2030. Schlegel F, editor. Paris: UNESCO Publ; 2015. 794 p.
388 (UNESCO science report).
- 389 17. Guleid FH, Oyando R, Kabia E, Mumbi A, Akech S, Barasa E. A bibliometric analysis of COVID-19
390 research in Africa. *BMJ Global Health*. 2021 May 1;6(5):e005690.
- 391 18. Lara Gongora AB, Werutsky G, Jardim DL, Nogueira-Rodrigues A, Barrios CH, Mathias C, et al. Impact
392 of the COVID-19 Pandemic on Oncology Clinical Research in Latin America (LACOG 0420). *JCO Glob*
393 *Oncol*. 2021 Apr;7:649–58.
- 394 19. Arienti F, Pansieri C, Pandolfini C, Biondi A, Bonati M. Globalization of pediatric research:
395 pharmacological RCTs in Latin America. *Ital J Pediatr*. 2019 Mar 4;45:29.
- 396 20. García-Vello P, Smith E, Elias V, Florez-Pinzon C, Reveiz L. Adherence to clinical trial registration in
397 countries of Latin America and the Caribbean, 2015. *Rev Panam Salud Publica*. 2018 Mar 16;42:e44.
- 398 21. Khamis AM, Bou-Karroum L, Hakoum MB, Al-Gibbawi M, Habib JR, El-Jardali F, et al. The reporting of
399 funding in health policy and systems research: a cross-sectional study. *Health Research Policy and*
400 *Systems*. 2018 Aug 17;16(1):83.
- 401 22. Hakoum MB, Jouni N, Abou-Jaoude EA, Hasbani DJ, Abou-Jaoude EA, Lopes LC, et al. Characteristics
402 of funding of clinical trials: cross-sectional survey and proposed guidance. *BMJ Open*. 2017 Oct
403 1;7(10):e015997.
- 404 23. Miranda JJ, Castro-Ávila AC, Salicrup LA. Advancing health through research partnerships in Latin
405 America. *BMJ*. 2018 Jul 16;362:k2690.
- 406 24. ANID. Gobierno lanza fondo de \$2.300 millones para investigación científica sobre COVID19 [Internet].
407 2020 [cited 2021 Jul 15]. Available from: [https://www.anid.cl/blog/2020/05/04/gobierno-lanza-fondo-de-](https://www.anid.cl/blog/2020/05/04/gobierno-lanza-fondo-de-2-300-millones-para-investigacion-cientifica-sobre-covid19/)
408 [2-300-millones-para-investigacion-cientifica-sobre-covid19/](https://www.anid.cl/blog/2020/05/04/gobierno-lanza-fondo-de-2-300-millones-para-investigacion-cientifica-sobre-covid19/)
- 409 25. MCTIC/FINEP/FNDCT. Soluções Inovadoras para o combate ao COVID-19 [Internet]. 2020 [cited 2021
410 Jul 15]. Available from: <http://www.finep.gov.br/chamadas-publicas/chamadapublica/641>
- 411 26. Agencia I+D+i. COVID-19: Convocatoria [Internet]. Argentina.gob.ar. 2020 [cited 2021 Jul 20]. Available
412 from: <https://www.argentina.gob.ar/ciencia/agencia/acciones-sobre-covid-19/covid-19-convocatoria>
- 413 27. Tulloch-Reid MK, Saravia NG, Dennis RJ, Jaramillo A, Cuervo LG, Walker SP, et al. Strengthening
414 institutional capacity for equitable health research: lessons from Latin America and the Caribbean. *BMJ*.
415 2018 Jul 16;362:k2456.
- 416 28. Thorson A, Aslanyan G, Brizuela V, Perez F, León RGP de, Reeder JC, et al. Research and research
417 capacity strengthening in the context of an emerging epidemic: Zika virus in Latin America. *International*
418 *Journal of Gynecology & Obstetrics*. 2020;148(S2):1–3.

- 419 29. Lancet T. COVID-19 in Latin America—emergency and opportunity. *The Lancet*. 2021 Jul
420 10;398(10295):93.
- 421 30. Kringos D, Carinci F, Barbazza E, Bos V, Gilmore K, Groene O, et al. Managing COVID-19 within and
422 across health systems: why we need performance intelligence to coordinate a global response. *Health Res*
423 *Policy Sys*. 2020 Dec;18(1):80.
- 424
- 425 S1 Supporting information.